Rapid System to Detect the Main Variants of SARS-CoV-2 in Biological Specimens

Marco Favaro  
“Tor Vergata” University

Paola Zampini  
Adaltis R&D s.r.l

Enrico S. Pistoia  
“Tor Vergata” University

Roberta Gaziano  
“Tor Vergata” University

Sandro Grelli  
“Tor Vergata” University

Carla Fontana (✉carla.fontana@uniroma2.it)  
“Tor Vergata” University

Research Article

Keywords: SARS CoV-2, mutation, deletion, variant

Posted Date: October 5th, 2021

DOI: https://doi.org/10.21203/rs.3.rs-918230/v1

License: 😎️ This work is licensed under a Creative Commons Attribution 4.0 International License.  
Read Full License
Abstract

Since its appearance in late 2019, SARS-CoV-2 has been reported to acquire substitutions more slowly than other RNA viruses, but its tendency to manifest recurrent deletions/mutations in the spike glycoprotein exceeds this slow replacement rate. To date, variants have been identified in many countries, some of which are transmitted efficiently and also present several lineages. The rapid identification of such variants is paramount to quickly implement containment measures. We developed a novel assay using traditional real-time PCR to detect the main reported variants of the spike gene of SARS-CoV-2. Primers and probes were designed to detect the following deletions and mutations as well as to cover all lineages known to date (B.1.617, B.1.617.1, B.1.617.2, B.1.617.3 and B.1.618): delta 69:70 and delta 144:145 deletions, which denote the UK variant (VOC 202012/01, now called Alpha); delta 242:244 deletion, which identifies the South African variant (now named Beta); delta 3675:3677 deletion in the ORF1a gene, which denotes the Brazilian variant (now called Gamma); and P681R mutation as well as delta 145:146 and delta 157:158 deletions, which identify the Indian variant (also known as Delta). Our assay will help clinical microbiologists and clinicians to rapidly recognize the presence of variants in biological samples (particularly nasopharyngeal swabs), and it may also be useful for epidemiological purposes in the early selection for successive tracing of patients harbouring virus variants that may be more diffusive and/or not responsive to vaccines.

Introduction

Since the appearance of SARS-CoV-2 in late 2019, people worldwide have presented with severe pneumonia at hospitals (1). Over time, the number of patients has rapidly increased. Community transmission of the virus, as well as antiviral treatments, can promote mutations in the virus, resulting in more virulent and/or more diffusive viruses with potentially higher mortality rates (2, 3). Although most of the emerging mutations do not have a significant impact on the spread of the virus or on its virulence, many others may provide selective advantages, including increased transmissibility, the ability to escape from the host immune response and resistance to antiviral drugs and vaccine effectiveness (2, 4, 5). To date are known at least eleven variants of SARS-CoV-2 named with the letters of the Greek alphabet to simplify their identification (from Alpha to Kappa) (5). Some variants pose an increased risk to global public health, and they are identified as Variants of Concern (VOCs: Alpha, Beta, Gamma and Delta,) in order to prioritize global monitoring and research (6).

The world is still facing these four main variants of SARS-CoV-2 which in detail are: VOC 202012/01 (501Y.V2; UK or Alpha variant); B1.351 (South African variant, or Beta); variant P.1 (Brazilian and Japanese variant or Gamma); and the Indian variant (specifically the B.1.617 lineage), known as Delta (5, 7–15). These variants likely have no impact on the mortality rate but have led to increased transmissibility, especially for the Brazilian and South African variants in which the K417N and E484K point mutations affect the efficacy of vaccines; in fact, a worsening epidemiological situation has been observed in many countries worldwide (7–9). The Delta variant may have been present for some time, but the first B.1.617 genome was recorded on October 5, 2020 in the global database (GISAID) (14). The Delta
variant comprises the B.1.617.1, B.1.617.2 and B.1.617.3 SARS-CoV-2 lineages, which have been increasingly detected in many countries (15). B.1.617 has several mutations (approximately thirteen) that are present in other variants of interest/concern, and it is controversial whether it has antigenic escape (15). To identify and trace these variants, researchers are using the whole-genome sequencing approach, which helps to define the emerging clades and identify single point mutations, but it is time consuming, expensive and available only in large laboratories or in national reference laboratories (16–19). Therefore, for the early identification of such variants, it is desirable to develop a molecular assay that is easy to use and cost efficient.

Here, we present a novel assay based on real-time PCR to detect SARS-CoV-2 variants located in the spike gene. Our assay detects the main deletions/mutations associated with the variants reported above, namely, the UK variant (Δ69-70 and Δ144:145 deletions; called VOC 202012/01), the South African variant (Δ242:244 deletion; also known as 501Y.V2), the Indian variant (P681R mutation as well as Δ145:146 and Δ157:158 deletions) and the Brazilian variant (Δ3675:3677 deletion in ORF1a; called 501Y.V3).

Materials And Methods

Samples

The present study did not include human participants but included leftover samples. For the assay, we used nucleic acids (NCs) extracted from 400 nasopharyngeal swabs (NFWs) routinely processed using a Nimbus instrument (Seegene Inc; Songpa-gu, Seoul 05548, Republic of Korea) and also confirmed using a qRT-PCR of our design as reported by Favaro et al (20). 5 µl of the eluate was used for the assay. NFWs were routinely delivered to the microbiology laboratory of our hospital from March to May 2021. Positive NFWs were established to be positive based on the results obtained using a commercial system (Allplex™ 2019-nCov Assay-Seegene) and the method described in our previous work (20). NCs were randomly selected among positive NFs and then processed using our assay.

Primers and Probes

The PCR assays used five sets of primers and probes of our own design. Four sets were used for the identification of the specific deletions, and one set of primers and probes, targeting human β–actin, was used as an internal control (IC). Table 1 shows the primer and probe sequences as well as labelling fluorophores for each probe. The primers and probes were synthesized by Metabion International AG (Planegg, Germany) and Bio-Fab (Rome, Italy).
| Primers                      | Sequence                                      |
|------------------------------|-----------------------------------------------|
| UK Forward Del 69-70         | GTT CCA TGC TCT MTC TGG G                     |
| UK Reverse Deletion 144:145  | GTG GTA AAC ACC CAA AAA TG                    |
| South Africa Forward Deletion 242:244 | GGT TTC AAA CTT TAC ATA G                  |
| South Africa Reverse Deletion 242:244 | ACC AGC TGT CCA ACC TGA AG              |
| Brazil Forward Deletion 3675:3677 | TTA CCT TCT CTT GCC ACT GT               |
| Brazil Reverse Del 3675:3677  | CTT ACA AAC TAG TAT CAA CC                  |
| Forward Deletion 145:146     | GAT CCA TTT TTG GGT GTT TAT AAA             |
| Indian Forward Deletion 157:158 | AGT TGG ATG GAA AGT GAG GTT TAT         |
| Indian common Reverse del 145:146/157:158 | CTGTTTTCTTCAAGGTCCATA |  |
| Forward Indian mutation P681R | ATC AGA CTC AGA CTA ATT CTC G              |
| Reverse Indian mutation P681R | CAA GTG ACA TAG TGT AGG CAA TG             |
| beta-actin Forward          | GAG GGT GAA CCC TGC AAA AG                  |
| beta-actin Reverse          | CCC TCT AAG GCT GCT CAA TG                  |

| Probes                      | Sequence & labelling fluorophores          |
|------------------------------|--------------------------------------------|
| VAR. Brazil probe           | 5’ Cy5,5 TGC CTG CTA GTT GGG TGA TGC GT 3’ BHQ3 |
| UK VAR probe                | 5’ TexasRed TTG GTA CTA CTT TAG ATT CGA AGA 3’BHQ2 |
| South Africa VAR probe      | 5’ Cy5 GTT ATT TGA CTC CTG GTG ATT C 3’ BHQ3 |
| Common probe Deletion 145: 146/157-158 | 5’ Fam CTA GTG CGA ATA ATT GCA CTT TTG A 3’ BHQ1 |
| Indian probe mut P681R      | 5’ Fam CAC GTA GTG TAG CTA GTC AAT CCA 3’ BHQ1 |
### Primers

| Primers            | Sequence                                      |
|--------------------|-----------------------------------------------|
| beta-actin probe   | 5’ HEX GGT GGG GCA GTG GGG GCC ACC TTGT 3’ BHQ1 |

### PCR conditions

The PCR working solution contained 5 pmol/µl primers and 2.5 pmol/µl probe (FAM, ROX, Cy5 or Cy5.5), except for the HEX-labelled probe, which was used at 3.0 pmol/µl. The final concentration for each reaction was 500 nM with 250 and 300 nM for primers and probes, respectively. Taq DNA polymerase and reverse transcriptase were both used according to the manufacturer’s instructions (PCR Biosystems Ltd., London, UK).

The real-time PCR conditions were as follows: reverse transcription for 10 minutes at 45°C; RT inactivation/Taq DNA polymerase activation for 2 minutes at 95°C; and 40 cycles of 15 seconds at 95°C and 30 seconds at 60°C. An Amplilab real-time machine (Adaltis SRL, Guidonia Montecelio, Italy) was used for the real-time PCR, and the results are shown in Table 2.

### Table 2

Possible results of our assay and interpretation criteria for samples with CT ≤ 38

| Fluorophores | FAM | ROX | Cy5 | Cy5.5 | HEX | Variant detected |
|--------------|-----|-----|-----|-------|-----|------------------|
| Interpretation | P681R | D145:146 | S D69:70 | S D242:244 | Orf1 D3675:3677 | IC |
|              | D157:158 | 144 |     |       |     |                  |
| Signals on each channel | POS | NEG | NEG | NEG | POS | INDIAN |
|              | NEG | POS | NEG | POS | POS | UNITED KINGDOM |
|              | NEG | NEG | NEG | POS | POS | BRAZIL |
|              | NEG | NEG | POS | NEG | POS | SOUTH AFRICA |
|              | NEG | NEG | NEG | NEG | POS | NEGATIVE |
|              | NEG | NEG | NEG | NEG | NEG | INVALID |
Sequence analysis

Amplicons from our assay were sequenced by the Sanger method using the Bio-Fab Research sequencing service (Rome, Italy). The following primers were used: S seq F 5’CCA CTA GTC TCT AGT CAG TGT GT 3’ and S seq R 5’GAG AGG GTC AAG TGC ACA GT 3’ (this work).

Results

A total of 400 SARS-CoV-2-positive NFs were used in the present study. Using the newly developed assay, 89 NFs (89/400; 22%) were positive for the UK variant, eight NFs were identified as South African variants (8/400; 2%), four NFs were identified as Brazilian/Japanese variants (4/400; 1%) and 24 (24/400, 6%) were Indian variants. The remaining samples were concluded as wild type.

To confirm the nature of the variants identified by our assay, all samples were analysed by sequence analysis.

Seventy-nine samples showed sequences compatible with Δ69:70 and Δ144:145 deletions, while ten samples showed mixed electropherograms with overlapping peaks. Figure 1 shows the UK variant Δ69:70 sequence, while Figure 2 shows a mixed electropherogram, resulting from the presence of two viral genomes (wild type and variant) in the same sample. The presence of two different lineages has previously been reported in the literature (3, 21). Table 2 shows the assay results. Of note, the presence of the Brazilian variant was verified by comparing the signals obtained in the different channels (FAM, ROX, Cy5 and Cy5.5) after the amplification assay. The UK and the Brazilian variants share the ORF1a deletion, while the Δ69:70 and Δ142:144 deletions are only present in the UK variant. Thus, if the PCR showed amplification curves in the ROX and Cy5.5 fluorophore channels (identifying Δ69:70 and Δ142:144 deletions as well as Δ3675:3677 deletion), it indicated that the UK variant was present. If only one signal for the Cy5.5 fluorophore (Δ 3675:3677 deletion) was present, the sample was positive for the Brazilian variant. Moreover, if an amplification curve was observed in the FAM channel, we could conclude that the Indian variant was present, even though the assay could not discriminate between the P681R mutation and the Δ145-146 or Δ157:158 deletion.

Discussion

VOC 202012/01 was the first variant identified in the United Kingdom in December 2020, but it has been traced back to September 2020 (22, 23). VOC 202012/01 is the predominant variant circulating in the UK, and it has become a great concern due to its increased transmissibility (2–23). The UK has implemented stricter nonpharmaceutical interventions (NPIs) to reduce risk of transmission (23, 24). Additionally, community transmission of VOC 202012/01 has been observed in Denmark, and in its response, the country has strengthened and prolonged the measures of containment. In December 2020, the 501Y.V2 variant was first identified in South Africa, and again, it is now one of the most prevalent. This V2 variant is characterized by increased transmissibility, and starting in January 2021, it has been identified in ten
EU/EEA countries (France is at the top), but also in Israel and the UK (24–28). Starting in December 2020, the B.1.617.1, B.1.617.2 and B.1.617.3 SARS-CoV-2 lineages were reported in India, and they have been increasingly detected in many countries (5, 6, 15). Therefore, early identification is extremely urgent to contain the spread of such variants (5, 6, 29). The reference method for identifying variants of SARS-CoV-2 is whole-genome sequencing, but it is expensive, time consuming and limited to use in large laboratories and reference laboratories. Our system has been demonstrated to be a rapid and cost-effective method to detect the main variants of the virus. Our assay is a simple real-time PCR and does not require expensive instrumentation. Furthermore, it is easy to use and can be introduced in any laboratory even in those that may not have advanced sequencing systems available. The advantage of our assay is that every hospital may quickly obtain the result of the variant circulation to promptly implement the infection control measures required to prevent further transmission in their setting (25–29).

Our assay has helped to quickly confirm/exclude the presence of the main SARS-CoV-2 variants, because our test is based on the direct detection of the presence of deletions/mutations, it is not affected by the potential co-presence of the wild-type SARS-CoV-2 virus in the specimens (which indicates a coinfection). Importantly, some of the commercially available tests have based their detection of the variants on the lack of amplification of the S gene. For both instances of a co-infection and re-infection (conditions that may generate the co-presence of two types of virus in the same sample/patient), the commercial tests may show a curve for the spike gene, but the latter belongs to amplification of the SARS-CoV-2 wild type virus, thereby masking the co-presence of a viral variant.

Finally, the results of our assay have provided information for the circulation of such variants in our location. Surprisingly, we found that the UK variant is widespread in our country, but it explains the massive and prolonged second longwave despite the lockdown measures implemented by our authorities (26). Moreover at the time of study also Indian variant was rising, and up to date it is dominant in our country (30). The global and rapid diffusion of SARS-CoV-2, combined with its ability to mutate, provides a terrible example of the prediction of the Nobel Laureate, Joshua Lederberg, who defined the fight against microbes as “Our wits versus their genes”.

**Declarations**

**Acknowledgements**

We wish to thank the COVID team (namely; Anna Altieri, Maria Cristina Bossa, Silvia Minelli, David Di Cave, Cartesio D’Agostini, Pier Paolo Paba, Domenico Ombres, Marco Ciotti: Laboratory of Microbiology & Virology, Polyclinic of “Tor Vergata”, Rome, Italy) for the support in processing routine nasopharyngeal swabs.

**Funding**

This study did not beneficed of any financial support.
Competing Interests

Carla Fontana has received a research grant by Quintiles/Angelini. Advisory Board: Angelini, Pfizer

Marco Favaro has received a research grant by Alifax R&D and Adaltis s.r.l

Ethics approval

The study did not include human participants but leftover samples. Specific informed consent are not required (as stated by “Independent Ethics Committee Tor Vergata Polyclinic” on 17 June 2020, approval no.102/20), having based this study on the use of leftover human specimens collected for routine analysis that would otherwise been discarded. The same specimens are "unlinked anonymized materials". This statement is in agreement to FDA “Guidance on Informed Consent for In Vitro Diagnostic Device Studies Using Leftover Human Specimens that are Not Individually Identifiable” April 25, 2006, and “Bioethical ed use di campion biologici umani” Pezzoli P. & Graziani MS biochemical clinic, 2008, vol. 32, n. 3.

Author contributors

Marco Favaro: Conceptualization-Equal, Data curation-Equal, Formal analysis-Equal, Investigation-Equal, Methodology-Equal, Project administration-Lead, Supervision-Lead, Writing-original draft-Equal, Writing-review & editing-Lead
Carla Fontana: Conceptualization-Equal, Data curation-Equal, Formal analysis-Equal, Investigation-Equal, Methodology-Equal, Project administration-Equal, Supervision-Lead, Validation-Equal, Visualization-Equal, Writing-original draft-Equal, Writing-review & editing-Lead
Paola Zampini: Data curation-Equal, Formal analysis-Equal, Investigation-Equal, Methodology-Equal
Enrico S. Pistoia: Data curation-Equal, Formal analysis-Equal, Investigation-Equal, Methodology-Equal
Roberta Gaziano: Writing-review & editing-Equal
Sandro Grelli: Data curation-Equal-supporting

References

1. Boni, M.F., Lemey, P., Jiang, X. et al. Evolutionary origins of the SARS-CoV-2 sarbecovirus lineage responsible for the COVID-19 pandemic. Nat Microbiol5, 1408–1417 (2020). https://doi.org/10.1038/s41564-020-0771-4
2. Huang, S.-W.; Wang, S.-F. SARS-CoV-2 Entry Related Viral and Host Genetic Variations: Implications on COVID-19 Severity, Immune Escape, and Infectivity. Int. J. Mol. Sci. 2021, 22, 3060. https://doi.org/ 10.3390/ijms22063060
3. Tillett RL, Sevinsky JR, Hartley PD, Kerwin H, Crawford N, Gorzalski A, Laverdure C, Verma SC, Rossetto CC, Jackson D, Farrell MJ, Van Hooser S, Pandori M. Genomic evidence for reinfection with SARS-CoV-2: a case study. Lancet Infect Dis. 2021 Jan;21(1):52-58. doi: 10.1016/S1473-3099(20)30764-7. Epub 2020 Oct 12. PMID: 33058797; PMCID: PMC7550103.

4. Zhou D, Dejnirattisai W, Supasa P, Liu C, Mentzer AJ, Ginn HM, Zhao Y, Duyvesteyn HME, Tuekprakhon A, Nualai R, Wang B, Paesen GC, Lopez-Camacho C, Slon-Campos J, Hallis B, Coombes N, Bewley K, Charlton S, Walter TS, Skelly D, Lumley SF, Dold C, Levin R, Dong T, Pollard AJ, Knight JC, Crook D, Lambe T, Clutterbuck E, Bibi S, Flaxman A, Bittaye M, Belij-Rammerstorfer S, Gilbert S, James W, Carroll MW, Kleereman P, Barnes E, Dunachie SJ, Fry EE, Mongkolsapaya J, Ren J, Stuart DI, Screaton GR. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell. 2021 Apr 29;184(9):2348-2361.e6. doi: 10.1016/j.cell.2021.02.037. Epub 2021 Feb 23. PMID: 33730597; PMCID: PMC7901269.

5. SARS-CoV-2 Variant Classifications and Definitions. Updated 14 September 2021. https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html

6. Tracking SARS-CoV-2 variants. https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/ accessed on September 16th 2021.

7. Abdool Karim SS, et al. New SARS-CoV-2 Variants - Clinical, Public Health, and Vaccine Implications. N Engl J Med. 2021. PMID: 33761203

8. Davidson et al. Characterisation of the transcriptome and proteome of SARS-CoV-2 reveals a cell passage induced in-frame deletion of the furin-like cleavage site from the spike glycoprotein Genome Medicine (2020) 12:68 https://doi.org/10.1186/s13073-020-00763-0

9. Lauring, A. S. & Hodcroft, E. B. Genetic variants of SARS-CoV-2 - What do they mean? JAMA (2021) doi:10.1001/jama.2020.27124.)

10. Bakhshandeh B, Jahanafrooz Z, Abbasi A, Goli MB, Sadeghi M, Mottaki MS, et al. Mutations in SARS-CoV-2; Consequences in structure, function, and pathogenicity of the virus. Microb Pathog. 2021 Mar 13;154:104831. Available at: https://www.ncbi.nlm.nih.gov/pubmed/33727169

11. European Centre for Disease Prevention and Control (ECDC). SARS-CoV-2 - increased circulation of variants of concern and vaccine rollout in the EU/EEA, 14th update. Stockholm: ECDC; 2021. Available at: https://www.ecdc.europa.eu/en/publications-data/covid-19-risk-assessment-variants-vaccine-fourteenth-update-february-2021

12. European Centre for Disease Prevention and Control (ECDC). SARS-CoV-2 variants of concern. Stockholm: ECDC; 2021. Available at: https://www.ecdc.europa.eu/en/covid-19/variants-concern

13. PANGO Lineages. Lineage B.1.617. PANGO Lineages; 2021. Available at: https://cov-lineages.org/lineages/lineage_B.1.617.html

14. GISAID Tracking of variants: G/452R (B.1.617+) available at https://www.gisaid.org/hcov19-variants/

15. European Centre for Disease Prevention and Control (ECDC). Emergence of SARS-CoV-2 B.1.617 variants in India and situation in the EU/EEA. May 2021. Available at
16. European Centre for Disease Prevention and Control. Sequencing of SARS-CoV-2. 23 December 2020. ECDC: Stockholm; 2020.

17. Oude Munnink BB, Nieuwenhuijse DF, Stein M, O'Toole Á, Haverkate M, Mollers M, et al. Rapid SARS-CoV-2 whole-genome sequencing and analysis for informed public health decision-making in the Netherlands. Nat Med [Internet]. 2020 September 16;26(9):1405–10. Available from: http://www.nature.com/articles/s41591-020-0997-y

18. Maljkovic Berry I, Melendrez MC, Bishop-Lilly KA, Rutvisutthinunt W, Pollett S, Talundzic E, et al. Next Generation Sequencing and Bioinformatics Methodologies for Infectious Disease Research and Public Health: Approaches, Applications, and Considerations for Development of Laboratory Capacity. J Infect Dis [Internet]. 2019 October 14; Available from: https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiz286/5586940

19. WHO Sequencing of SARS-CoV-2A guide to implementation for maximum impact on public health 8 January 2021

20. Favaro M, Mattina W, Pistoia ES, Gaziano R, Di Francesco P, Middleton S, D’Angelo S, Altarozzi T, Fontana C. 2021. A new qualitative RT-PCR assay detecting SARS-CoV-2. Scientific Report (in press)

21. RDS Jr, Benites LF, Lamarca AP, de Almeida LGP, Hansen AW, Gularte JS, Demoliner M, Gerber AL, de C Guimarães AP, Antunes AKE, Heldt FH, Mallmann L, Hermann B, Ziułkowski AL, Goes V, Schallenberger K, Fillipi M, Pereira F, Weber MN, de Almeida PR, Fleck JD, Vasconcelos ATR, Spilki FR. Pervasive transmission of E484K and emergence of VUI-NP13L with evidence of SARS-CoV-2 co-infection events by two different lineages in Rio Grande do Sul, Brazil. Virus Res. 2021 Ap15;296:198345. doi: 10.1016/j.virusres.2021.198345. Epub 2021 Feb 22. PMID: 33631222;

22. European Centre for Disease Prevention and Control. Risk related to spread of new SARS-CoV-2 variants of concern in the EU/EEA, first update – 21 January 2021. ECDC: Stockholm; 2021.

23. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England bioRxiv(2020)doi:10.1101/2020.12.24.20248822.

24. Eubank S, Eckstrand I, Lewis B, Venkatramanan S, Marathe M, Barrett CL. Commentary on Ferguson, et al., "Impact of Non-pharmaceutical Interventions (NPIs) to Reduce COVID-19 Mortality and Healthcare Demand". Bull Math Biol. 2020 Apr;82(4):52. doi: 10.1007/s11538-020-00726-x. PMID: 32270376; PMCID: PMC7140590.

25. Tang, J. W., Toovey, O., Harvey, K. N., & Hui, D. (2021). Introduction of the South African SARS-CoV-2 variant 501Y.V2 into the UK. The Journal of infection, 82(4), e8–e10. https://doi.org/10.1016/j.jinf.2021.01.007

26. Risk Assessment: Risk related to the spread of new SARS-CoV-2 variants of concern in the EU/EEA – first update https://www.ecdc.europa.eu/en/publications-data/covid-19-risk-assessment-spread-new-variants-concern-eueea-first-update
27. European Centre for Disease Prevention and Control (ECDC). Risk Assessment: Risk related to the spread of new SARS-CoV-2 variants of concern in the EU/EEA – first update Jan 2021. Available at https://www.ecdc.europa.eu/en/publications-data/covid-19-risk-assessment-spread-new-variants-concern-eueea-first-update

28. Xiaolu Tang, Changcheng Wu, Xiang Li, Yuhe Song, Xinmin Yao, Xinkai Wu, Yuange Duan, Hong Zhang, Yirong Wang, Zhaohui Qian, Jie Cui, Jian Lu, On the origin and continuing evolution of SARS-CoV-2, National Science Review, Volume 7, Issue 6, June 2020, Pages 1012–1023, https://doi.org/10.1093/nsr/nwaa036

29. Chakraborty D, Agrawal A, Maiti S. Rapid identification and tracking of SARS-CoV-2 variants of concern. Lancet. 2021 Apr 10;397(10282):1346-1347. doi: 10.1016/S0140-6736(21)00470-0. Epub 2021 Mar 23. PMID: 33765408; PMCID: PMC7984862

30. Novel coronavirus. Available at the web site of Italian Ministry of Health https://www.salute.gov.it/portale/nuovocoronavirus/archivioNotizieNuovoCoronavirus.jsp?linga=english.

Figures

Figure 1

Electropherogram peak analyses showing the sequence of “mixed type sample” blue arrows indicate the presence of overlapped peaks in the eletropherogram due to the co-presence of wild type as well as variant of SARS-CoV-2

Figure 2
Electropherogram peak analyses showing the sequence of one sample concluded as “UK variant” with the Δ69/70 deletion